Filter by Cancer
- Bladder cancer
- Myeloma
- Leukemia
- Breast cancer
- Colon cancer
- Esophageal cancer
- Kidney cancer
- Colorectal cancer
- Liver cancer
- Lung cancer
- Hodgkin's disease
- Lymphoma
- Mesenteric Lymphadenitis
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Rectal cancer
- Skin cancer
- Small Intestine cancer
- Spleen cancer
- Stomach cancer
- Ureteral cancer
- Urethral cancer
- Uterine cancer
- White blood cells
ADC
- A166 ADCKlus Pharma
- AB-3A4 ADCAlethia Biotherapeutics
- ABBV-176 (ABV176)Abbvie
- ABBV-321AbbVie
- ABBV-3373AbbVie
- AbGn-107 (Ab1-18Hr1)AbGenomics BV | Taiwan Branch
- AbGn-108AbGenomics International
- AbGn-110AbGenomics International
- ADCT-502ADC Terapeutics
- ADCT-601ADC Therapeutics
- ADCT-602 (hLL2-cys-PBD)ADC Therapeutics
- ADCT-701ADC Therapeutics
- AGS-16C3F (AGS 16C3F / AGS-16M8F)Agensys/Astellas
- AGS-16M8F (AGS 16C3F / AGS-16C3F)Agensys/Astellas
- AGS62P1Agensys/Astellas
- ALT-P73SBIO | Alteogen
- AMG 224Amgen
- AMG-595Amgen
- AMG172Amgen, Inc
- Anetumab corixetan
- Anetumab Ravtansine | BAY 94-9343Bayer HealthCare Pharmaceuticals in association with ImmunoGen Inc.
- Anti-ADAM9 ADC (Anti-ADAM9-sulfoSPDB-DM4)Macrogenics and ImmunoGen
- Anti-ADAM9 ADC (Anti-ADAM9(C442)-DGN549)Macrogenics and ImmunoGen
- Anti-CD19 ATAC (anti-CD19 ADC)Heidelberg Pharma/Wilex
- Anti-CD22-NMS249Genentech and Nerviano Medical Sciences
- Anti-CD70-ADC (CD70-ADC)Ambrx
- Anti-cMET ADC (CBT-161)Sorrento Therapeutics
- Anti-endosialin-MC-VC-PABC-MMAEGenzyme
- Anti-ETBR (RG-7636)Genentech/Roche
- anti-HER-3 ADCMediaPharma
- anti-TEM-1 Antibody-Drug Conjugate (TEM-1-ADC).MediaPharma S.r.l.
- Anti-TM4SF1 ADCThe Center for Vascular Biology Research and the Departments of Angiex; Pfizer; Pathology, Beth Israel Deaconess Medical Center (BIDMC); Harvard Medical School, Boston, Massachusetts
- Aprutumab ixadotin | BAY 1187982Bayer HealthCare Pharmaceuticals
- AR-001 | YBL-001Y-Biologics
- ARX517-PSMA-ADCAmbrx
- ARX788 HER2 ADC | ARX788Zhejiang Medicine Co. | Ambrx
- ASG-22CEAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
- ASN-004 (ASN 004)Asana Biosciences
- AVID100Formation Biologics | Forbius
- AVID300 | AVID 300Formation Biologics
- Azintuxizumab Vedotin | ABBV-838AbbVie
- Azonafide-ADCOncolinx
- BA3011 | CAB-Axl-ADC (CAB-anti-Axl-ADC)BioAtla
- BA3021 | Anti-ROR2 ADC | CAB-ROR2-ADCBioAtla
- BAY79-4620Bayer HealthCare
- Belantamab mafodotin | GSK2857916 | J6M0-mcMMAFGlaxoSmithKline (GSK) Co-developer: Seattle Genetics
- BIIB-015 | BIIB015Biogen
- Bivatuzumab mertansine | Anti-CD44v6-DM1 | BIWI-1Boehringer Ingelheim | ImmunoGen
- BL-B029A1Systimmune
- BL-M002A2Systimmune
- BL-M005A2Systimmune
- Brentuximab vedotin | SGN35 | Adcetris®Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan)
- Bstrongximab-ADCCureMeta
- BT1718 (BT 1718)Bicycle Therapeutics
- c-MET ADCConcortis Biotherapeutics
- Camidanlumab tesirine | ADCT-301 | HuMax-TAC-ADCGenmab | ADC Therapeutics
- Cantuzumab mertansine | huC242-DM1 | SB-408075GlaxoSmithKline (GSK) / ImmunoGen
- Cantuzumab Ravtansine | IMGN-242ImmunoGen
- CC-99712 - Anti-BCMA ADCCelgene / Bristol-Myers Squibb Sutro
- CD184-Dasatinib (CD184-Dasatinib-ADC)Ambrx
- CD184-FK506Ambrx
- CD22-4APCatalent Pharma Solutions and Triphase Accelerator Corporation
- CD70-glucocorticoid ADCMerck & Co and Ambrx
- CDX-014Celldex Therapeutics
- Cetuximab sarotalocan | ASP-1929 | RM-1929Rakuten Medical (Aspyrian Therapeutics)
- Cirmtuzumab Vedotin | UC-961ADC3Thomas Kipps, University of California, San Diego
- Clivatuzumab TetraxetanImmunmedics
- CMB-401 | hCTMO1-calicheamicin | CDP-671Pfizer (Wyeth Pharmaceuticals); Celltech
- Cofetuzumab pelidotin | PF-06647020Pfizer Stemcentrx (AbbVie) In collaboration with Indiana University
- Coltuximab Ravtansine | SAR 3419ImmunoGen (previously also Sanofi)
- CX-2009Cytomx
- Cymac-001 (anti-CD163-dexamethasone ADC)Affinicon
- D3-GPC2-PBD (anti-GPC2 ADC)Children's Hospital of Philadelphia (CHOP
- DEDN6526A (RG-7636 / RG7636)Genentech/Roche
- Denintuzumab mafodotin | SGN-CD19A | SGN-19A | hBU12-491Seattle Genetics
- Depatuxizumab Mafodotin | ABT-414AbbVie (prior sponsor, Abbott)
- Derlotuximab BiotinPeregrine Pharmaceuticals
- DHES0815AGenentech/Roche
- Disitamab Vedotin | RC-48 | RC 480-ADC | RC48Yantai Rongchang Biological Engineering and RemeGen (Shandong China)
- DMOT4039A (DMOT-4039A / RG7600 / RG 7600)Genentech Inc. (South San Francisco, CA, USA) / Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
- DS-1062 (TROP2 ADC)Daiichi Sankyo
- DS-7300 (B7-H3 ADC)Daiichi Sankyo Company
- DSTA4637S (Anti-S. aureus TAC; RG7861)Genentech
- EC1169Endocyte
- EC2629Endocyte
- EDC1 (DYS-ADC)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
- EDC9 (EDC-CD20)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
- EDO-772P/B776Mundipharma EDO GmbH
- EDO-B278Mundipharma EDO GmbH
- Enapotamab vedotin | HuMax-AXL-ADC | AXL-107-MMAEGenmab
- Enfortumab Vedotin | ASG-22ME | ASG-22MSEAstellas Pharma (Agensys) / Seattle Genetics
- EP-400Esperance Pharmaceuticals
- Epitumomab cituxetan
- Epratuzumab–SN-38Immunomedics
- EV20/MMAFMediapharma
- Gemtuzumab ozogamicin | Mylotarg®Pfizer (Wyeth)
- Glembatumumab vedotin | CDX-011Celldex Therapeutics, Inc.
- GM103GamaMabs
- GTB-1550 | OXS-1550 | DT2219ARLGT Biopharma. Previously known as Oxis Biotech (Georgetown Translational Pharmaceuticals)
- HDP-101 (Anti-CD269-ADC; Anti-CD269-amanitin-ADC)Heidelberg Pharma
- Hertuzumab VedotinRongchang Pharmaceuticals / MabPlex (Yantai, China).
- HKT288 (CDH6-ADC)Novartis and ImmunoGen
- HTI-1511Halozyme
- HuMAB-5B1-ATACWilex/Heidelberg Pharma in collaboration with MabVax
- Ibritumomab tiuxetanBiogen Schering AG Spectrum Pharmaceuticals
- IGN523Igenica Biotherapeutics
- IGN786Igenica Biotherapeutics
- IKS01Iksuda Therapeutics (formerly known as Glythera)
- IKS02Iksuda Therapeutics (formerly known as Glythera)
- IKS03Iksuda Therapeutics (formerly known as Glythera)
- IKS04Iksuda Therapeutics (formerly known as Glythera)
- Iladatuzumab vedotin | DCDS0780A | RO7032005Genentech F. Hoffmann-La Roche
- IMAB027-vcMMAEGanymed Pharmaceuticals | Astellas
- IMAB362-vcMMAEAstellas (Ganymed Pharmaceuticals)
- IMB-201ImmunoBiochem
- IMB-202ImmunoBiochem
- IMGN 289ImmungoGen
- IMGN 779 | IMGN779ImmunoGen, Inc.
- IMGN-242ImmunoGen
- IMGN-388ImmunoGen
- IMGN-633 (AVE9633)ImmunoGen
- IMGN632 | IMGN 632ImmunoGen
- IMMU-140 (anti-HLA-DR-SN-38 ADC)Immunomedics
- Indatuximab Ravtansine | BT-062ImmunoGen | BioTest
- Indusatumab Vedotin | MLN-0264 | TAK-264Takeda / Millennium Pharmaceuticals
- Inotuzumab ozogamicin (CMC-544) | BESPONSA®Pfizer (Wyeth Pharmaceuticals)
- IPH43Innate Pharma in collaboration with AstraZeneca
- KTN0125Kolltan Pharmaceuticals
- KTN0182AKolltan Pharmaceuticals
- Labetuzumab govitecan | IMMU-130Immunomedics
- Ladiratuzumab vedotin | SGN-LIV1A | Anti-LIV-1 ADCSeattle Genetics
- Laprituximab emtansine | IMGN-289 | IMGN289ImmunoGen
- LCB14-0110 (Herceptin-LC-LBG-MMAF)Legochem Biosciences and Fosun Pharma
- LCB14-15nmLegoChem Biosciences and Takeda
- LCB14-15xxLegoChem Biosciences and Y-Biologics
- LCB14-15xx (NNV019)LegoChem Biosciences and Nordic Nanovector
- LCB14-17nnLegoChem Biosciences and Gree Cross
- LCB14-19nmLegoChem Biosiences and Samsung Medical Center
- LCB14-2nmLegoChem Biosciences and Seasun Biomaterials
- Lifastuzumab Vedotin | RG-7599 | DNIB0600ARoche, F. Hoffmann-La Roche / Genentech
- Lilotomab satetraxetanNordic Nanovector ASA
- Loncastuximab tesirine | ADCT-402ADC Therapeutics SARL
- LOP628 (LOP-628)Novartis Pharmaceuticals
- Lorvotuzumab mertansine | IMGN-901ImmunoGen
- Losatuxizumab vedotin | ABBV-221AbbVie
- Lupartumab amadotin | BAY 1129980Bayer
- LY3076226Eli Lilly and Company
- MDX-060 / iratumumabMedarex/Bristol-Myers Squibb
- MDX-1203 | BMS936561Medarex | Bristol-Myers Squibb
- MEDI-547MedImmune
- MEDI3726 | ADCT-401ADC Therapeutics in collaboration with MedImmune/AstraZeneca
- MEDI4276 (MEDI 4276)Medimmune / AstraZeneca
- MEN1309 | OBT076Co-developed by Menarini Ricerche and Oxford BioTherapeutics
- MGC018; Anti-B7-H3 ADCMacroGenics
- MI130004PharmaMar
- Milatuzumab doxorubicin (hLL1-DOX | IMMU-110)Immunomedics
- Mirvetuximab Soravtansine | IMGN-853ImmunoGen (Cambridge MA USA)
- Mirzotamab Clezutoclax | ABBV-155AbbVie
- MLN-2704 | MLN2704Millennium/ Takeda
- MM-302Merrimack Pharmaceuticals, Inc.
- MORAb-202Morphotek®, a subsidiary of Eisai
- Naratuximab emtansine | IMGN529 | K7153A | Debio 1562ImmunoGen Debiopharm Internaltional
- NBE-001NBE Therapeutics
- NBE-002 - ROR-1NBE Therapeutics GmbH
- NBE-003NBE Therapeutics
- NC-6201 (ADCM-E7974)NanoCarrier Co.,Ltd (Japan) and Eisai
- NV101 (Doxorubicin-anti-CD99)NanoValent Pharmaceuticals
- NV102 (Doxorubicin-anti-CD19)NanoValent Pharmaceuticals
- NV103 (Irinotecan-anti-CD99)NanoValent Pharmaceuticals
- OBI-999 | Anti-Globo H ADCOBI Pharma
- OMTX503 (Anti-MTX3:Nigrin Immunoconjugate)Oncomatryx Biopharma
- OMTX705 (Anti-MTX5:Cytolysin ADC)Oncomatryx Biopharma
- Patritumab DeruxtecanDaiichi SankyoThe antibody part is developed in collaboration with Amgen.
- PCA062 (PCA-062)ImmunogGen and Novartis
- PEN-221Tarveda Therapeutics
- PF 06263507 (A1-mcMMAF | Anti-5T4 monoclonal antibody | PF-06263507 | PF06263507)Oxford BioMedica; Pfizer (Wyeth)
- PF-06647263 (anti-EFNA4-ADC)Pfizer
- PF-06650808 (Anti-NOTCH3 ADC)Pfizer (Wyeth)
- PF-06664178 | PF06664178 | PF 06664178Pfizer (Wyeth)
- PF-06688992 | PF06688992Memorial Sloan-Kettering Cancer Center; Pfizer
- PF-06804103 (Anti-NG-HER2 ADC)Pfizer
- Pinatuzumab vedotin | RG-7593 | DCDT2980S | DCDT-2989SGenentech / Roche, F. Hoffmann-La Roche (Roche)
- Polatuzumab vedotin | Polivy™ | RG-7596 | DCDS4501A | DCDS-4501AGenentech / Roche, F. Hoffmann-La Roche
- Praluzatamab RavtansineCytomX Therapeutics
- PSMA-ADCProgenics Pharmaceuticals, Inc. (Tarrytown NY USA)
- Q5-Drug ConjugateAlteogen
- REGN2878-DM1 (Anti-PRLR-ADC)Regeneron
- RG-7598 (DFRF 4539A / RG7598 / RG 7598)Genentech/Roche
- RG-7841 (Anti-Ly6E / DLYE5953A)Genentech/Roche (in collaboration with Seattle Genetic)
- RG7986Genentech/Roche
- Rolinsatamab talirineAbbVie
- Rovalpituzumab tesirine | Rova-T | SC0001Stemcentrx (now part of AbbVie)
- Sacituzumab govitecan | IMMU-132 | hRS7-SN38Immunomedics
- Samrotamab Vedotin | ABBV-085 | PR-1498487-MMAEAbbVie, Inc.
- SAR 566658 (SAR566658)Sanofi; ImmunoGen
- SAR408701 | SAR 408701Sanofi | ImmunoGen
- SAR428926ImmunoGen; Sanofi
- Satoreotide tetraxetan
- SC-006AbbVie | Stemcentrx
- SC16LD6.5Stem CentRx
- Serclutamab TalirineAbbVie
- SGN CD70 A | SGN-CD70A (superseding SGN-75)Seattle Genetics
- SGN-15 | BMS-182248 | BR96-DOXSeattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)
- SGN-CD123A
- SGN-CD19BSeattle Genetics
- SGN-CD352aSeattle Genetics
- Sirtratumab vedotin (ASG-15ME)Co-developed by Astellas/Agensys and Seattle Genetics
- SNG-8023 ADCShenogen Pharma Group
- Sofituzumab vedotin | Anti-MUC16 ADC | RG7458 | DMUC5754ARoche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
- ST1Siamab Therapeutics
- STRO-001 (Anti-CD74-ADC)Sutro Biopharma
- SΤRO-002Sutro Biopharma
- Tabituximab Barzuxetan | OTSA-101-DTPAOncoTherapy Science (Japan) Centre Leon Berard
- Tacatuzumab Tetraxetan
- Tamrintamab Pamozirine | Anti-DPEP3 ADCAbbVie Stemcentrx LLC
- Telisotuzumab Vedotin | ABBV 399 | ABBV399AbbVie
- TGM-001Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-002Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-003Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-004Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-005Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- Tisotumab Vedotin | HuMax®-TF-ADCCo-developed by Genmab and Seattle Genetics
- Trastuzumab deruxtecan (DS-8201, DS-8201a)Daiichi Sankyo Inc.
- Trastuzumab duocarmazine | SYD985Synthon Biopharmaceuticals
- Trastuzumab Emtansine | T-DM1 | Kadcyla®Genentech RocheIn collaboration with ImmunoGen
- TRPH-222 (CD22-4AP)Triphase Accelerator Corporation, in collaboration with Celgene
- U3-1402 | HER3 ADCDaiichi Sankyo
- Vadastuximab talirine | SGN-CD33ASeattle Genetics
- Vandortuzumab vedotin (RG7450; DSTP3086S)Genentech/ F. Hoffmann-La Roche (Roche)
- VIS705Visterra
- Vorsetuzumab mafodotin (SGN-75)Seattle genetics
- VYNFINIT® | Vintafolide (EC145/MK 8109)Endocyte, Merck/MSD
- XMT-1522 | TAK-522Mersana Therapeutics in collaboration with Takeda.Antibody development: Adimab
- XMT-1536Mersana Therapeutics
- ZV05-ADC (5T4-MMAF ADC)Zova Biotherapeutics (Zova Bio); Concortis Biotherapeutics (a subsidiary of Sorrento Therapeutics)
- ZV203Concortis Biotherapeutics
